Login to Your Account



Semma raises $114M to advance cell therapy for diabetes

By Michael Fitzhugh
Staff Writer

Friday, December 1, 2017

Semma Therapeutics Inc. has raised $114 million in a series B financing aimed at carrying its stem cell-derived beta cells, a potential therapy for people living with type 1 diabetes, through proof-of-concept studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription